Riber S.A. of Bezons, France, which manufactures molecular beam epitaxy (MBE) systems as well as evaporation sources and effusion cells, has reported a 23% rise in revenue from €5.7m in first-half 2015 to €7m in first-half 2016, comprising 56% from Asia (up from 43%), 24% from the USA (up from 6%) and 20% from Europe (down from 40%).
MBE systems sales were solid during first-half 2016. The number of systems sold has fallen from four research machines in first-half 2015 to two machines, but one of these was a production machine, so revenue rose by 29% from €2.8m to €3.6m.
Sales of services & accessories (€2.4m, up 14% from €2.1m) and cells & sources (€1m, up 25% from €0.8m) are up 17% collectively on first-half 2015. This growth reflects Riber's improved commercial performance in its long-standing markets, combined with the development of its position in the USA following its acquisition of MBE Control Solutions of Santa Barbara, CA, USA in March 2015.
Order have risen by 40% from €6.3m in first-half 2015 to €8.8m in second-half 2016. Specifically, MBE system orders (for delivery in 2016) have risen by 33% from €4.5m to €6m, comprising five machines (including one production machine). Orders for services & accessories have grown strongly by 90% from €1.1m to €2.1m. Orders for cells & sources are level at €0.7m.
Riber says that, against a backdrop of moderate growth for the MBE market, the upturn in commercial business has been driven by the signing of several new contracts and supported by development of the range of services and accessories offered.
Based on these factors, Riber confirms its full-year 2016 revenue target of at least 30% growth on 2015.
